Ovarian masses predominated (n=106; 48.6%), reflecting the proportionately larger number of female patients, followed by extragonadal sites (EG) (n=72; 33%) and lastly testicular masses (n=40; 18.3%). Yolk sac tumours were most common (n=119; 54.6%), followed by dysgerminomas (n=53; 24.3%), mixed germ cell tumours (n=32; 13.8%), embryonal carcinomas (n=8; 3.7%), seminomas (n=4; 1.8%) and choriocarcinomas (n=2; 0.9%). Neither tumour site nor histology (p=0.28) was predictive of outcome.